Targeting small airways, a step further in asthma management

Clinical Respiratory Journal

Volumn 5, Issue 3, 2011, Pages 131-135

  Bjermer, Leif ^a  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

HFA BDP; Inhaled corticosteroids; Small airways; Ultrafine particles

Indexed keywords

BECLOMETASONE DIPROPIONATE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CHLOROFLUOROCARBON; NITRIC OXIDE;

AEROSOL; ASTHMA; IMAGING; LUNG CLEARANCE; PARTICLE SIZE; PRIORITY JOURNAL; RESPIRATORY FUNCTION; REVIEW;

ADMINISTRATION, INHALATION; AEROSOLS; ANTI-ASTHMATIC AGENTS; ASTHMA; BRONCHIOLES; BRONCHITIS; DRUG RESISTANCE; HUMANS; LUNG; PARTICLE SIZE; POPULATION SURVEILLANCE;

EID: 79959351296     PISSN: 17526981     EISSN: 1752699X     Source Type: Journal    
DOI: 10.1111/j.1752-699X.2011.00240.x     Document Type: Review

References (35)

1. Bjermer L. Time for a paradigm shift in asthma treatment: from relieving bronchospasm to controlling systemic inflammation. J Allergy Clin Immunol 2007;120(6): 1269-75.
2. Bjermer L. History and future perspectives of treating asthma as a systemic and small airways disease. Respir Med 2001;95(9): 703-19.
3. Macklem PT. The physiology of small airways. Am J Respir Crit Care Med 1998;157(5 Pt 2): S181-3.
4. Lee YM, Park JS, Hwang JH, etal. High-resolution CT findings in patients with near-fatal asthma: comparison of patients with mild-to-severe asthma and normal control subjects and changes in airway abnormalities following steroid treatment. Chest 2004;126(6): 1840-8.
5. Frey U, Suki B. Complexity of chronic asthma and chronic obstructive pulmonary disease: implications for risk assessment, and disease progression and control. Lancet 2008;372(9643): 1088-99.
6. Williamson PA, Clearie K, Menzies D, Vaidyanathan S, Lipworth BJ. Assessment of small-airways disease using alveolar nitric oxide and impulse oscillometry in asthma and COPD. Lung 2010;189(2): 121-9.
7. Kaminsky DA, Irvin CG, Gurka DA, etal. Peripheral airways responsiveness to cool, dry air in normal and asthmatic individuals. Am J Respir Crit Care Med 1995;152(6 Pt 1): 1784-90.
8. Kraft M, Djukanovic R, Torvik J, etal. Evaluation of airway inflammation by endobronchial and transbronchial biopsy in nocturnal and nonnocturnal asthma. Chest 1995;107(Suppl. 3): 162S.
9. in 't Veen JC, Beekman AJ, Bel EH, Sterk PJ. Recurrent exacerbations in severe asthma are associated with enhanced airway closure during stable episodes. Am J Respir Crit Care Med 2000;161(6): 1902-6.
10. Bai TR, Vonk JM, Postma DS, Boezen HM. Severe exacerbations predict excess lung function decline in asthma. Eur Respir J 2007;30(3): 452-6.
11. Westergren-Thorsson G, Larsen K, Nihlberg K, etal. Pathological airway remodelling in inflammation. Clin Respir J 2010;4(Suppl. 1): 1-8.
12. Nihlberg K, Andersson-Sjöland A, Tufvesson E, Erjefält JS, Bjermer L, Westergren-Thorsson G. Altered matrix production in the distal airways of individuals with asthma. Thorax 2010;65(8): 670-6.
13. Lehtimäki L, Kankaanranta H, Saarelainen S, Turjanmaa V, Moilanen E. Increased alveolar nitric oxide concentration in asthmatic patients with nocturnal symptoms. Eur Respir J 2002;20(4): 841-5.
14. Kraft M, Martin RJ, Wilson S, Djukanovic R, Holgate ST. Lymphocyte and eosinophil influx into alveolar tissue in nocturnal asthma. Am J Respir Crit Care Med 1999;159(1): 228-34.
15. Aronsson D, Tufvesson E, Bjermer L. Comparison of central and peripheral airway involvement before and during methacholine, mannitol and eucapnic hyperventilation challenges in mild asthmatics. Clin Respir J 2011;5(1): 10-18.
16. Aronsson D, Tufvesson E, Ankerst J, Bjermer L. Allergic rhinitis with hyper-responsiveness differ from asthma in degree of peripheral obstruction during metacholine challenge test. Clin Physiol Funct Imaging 2008;28(2): 81-5.
17. Tufvesson E, Aronsson D, Ankerst J, George SC, Bjermer L. Peripheral nitric oxide is increased in rhinitic patients with asthma compared to bronchial hyperresponsiveness. Respir Med 2007;101(11): 2321-6.
18. Andersson C, Bergqvist A, Mori M, Mauad T, Bjermer L, Erjefält J. Mast-cell associated alveolar inflammation in patients with atopic uncontrolld asthma. J Allergy Clin Immunol 2011;127(4): 905-12.e7.
19. Kearley J, Erjefalt JS, Andersson C, etal. IL-9 governs allergen-induced mast cell numbers in the lung and chronic remodeling of the airways. Am J Respir Crit Care Med 2011;183(7): 865-75.
20. Storms W, Chervinsky P, Ghannam AF, Bird S, Hustad CM, Edelman JM. A comparison of the effects of oral montelukast and inhaled salmeterol on response to rescue bronchodilation after challenge. Respir Med 2004;98(11): 1051-62.
21. Bjermer L, Bisgaard H, Bousquet J, etal. Montelukast and fluticasone compared with salmeterol and fluticasone in protecting against asthma exacerbation in adults: one year, double blind, randomised, comparative trial. BMJ 2003;327(7420): 891.
22. Nieto A, Pamies R, Oliver F, Medina A, Caballero L, Mazon A. Montelukast improves pulmonary function measured by impulse oscillometry in children with asthma (Mio study). Respir Med 2006;100(7): 1180-5.
23. Berry M, Hargadon B, Morgan A, etal. Alveolar nitric oxide in adults with asthma: evidence of distal lung inflammation in refractory asthma. Eur Respir J 2005;25(6): 986-91.
24. Esmailpour N, Högger P, Rabe KF, Heitmann U, Nakashima M, Rohdewald P. Distribution of inhaled fluticasone propionate between human lung tissue and serum in vivo. Eur Respir J 1997;10(7): 1496-9.
25. Ulrik CS, Lange P. Targeting small airways in asthma: improvement in clinical benefit? Clin Resp J 2011; doi:10.1111/j.1752-699X.2010.00235.x.
26. Kraft M. The distal airways: are they important in asthma? Eur Respir J 1999;14(6): 1403-17.
27. van den Berge M, ten Hacken NH, Cohen J, Douma WR, Postma DS. Small airway disease in asthma and COPD: clinical implications. Chest 2011;139(2): 412-23.
28. Fowler SJ, Orr LC, Wilson AM, Sims EJ, Lipworth BJ. Dose-response for adrenal suppression with hydrofluoroalkane formulations of fluticasone propionate and beclomethasone dipropionate. Br J Clin Pharmacol 2001;52(1): 93-5.
29. Haley KJ, Sunday ME, Wiggs BR, etal. Inflammatory cell distribution within and along asthmatic airways. Am J Respir Crit Care Med 1998;158(2): 565-72.
30. Derom E, Louis R, Tiesler C, Engelstätter R, Kaufman JM, Joos GF. Effects of ciclesonide and fluticasone on cortisol secretion in patients with persistent asthma. Eur Respir J 2009;33(6): 1277-86.
31. Rohatagi S, Luo Y, Shen L, etal. Protein binding and its potential for eliciting minimal systemic side effects with a novel inhaled corticosteroid, ciclesonide. Am J Ther 2005;12(3): 201-9.
32. Fishwick D, Bradshaw L, Macdonald C, etal. Cumulative and single-dose design to assess the bronchodilator effects of beta2-agonists in individuals with asthma. Am J Respir Crit Care Med 2001;163(2): 474-7.
33. Leach CL, Colice GL. A pilot study to assess lung deposition of HFA-beclomethasone and CFC-beclomethasone from a pressurized metered dose inhaler with and without add-on spacers and using varying breathhold times. J Aerosol Med Pulm Drug Deliv 2010;23(6): 355-61.
34. Sarangapani R, Wexler AS. The role of dispersion in particle deposition in human airways. Toxicol Sci 2000;54(1): 229-36.
35. Lambert AR, O'Shaughnessy P, Tawhai MH, Hoffman EA, Lin CL. Regional deposition of particles in an image-based airway model: large-eddy simulation and left-right lung ventilation asymmetry. Aerosol Sci Technol 2011;45(1): 11-25.